CD40L-transfected myeloma cells transfer prolonged immunity in vivo

In Vivo

Volumn 24, Issue 1, 2010, Pages 45-48

  Kim, Young ^a   Strehl, John W ^a   Sievers, Elisabeth ^a   Gorschlüter, Marcus ^a   Brossart, Peter ^a   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

CD40L; Gene therapy; Myeloma; Plasmocytoma

Indexed keywords

CD40 LIGAND;

ANIMAL CELL; ARTICLE; CELL TRANSFER; CONTROLLED STUDY; IMMUNITY; IN VIVO STUDY; MOUSE; MYELOMA CELL; NONHUMAN; TUMOR GROWTH; TUMOR REGRESSION;

EID: 77649116433     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. D'Amico G, Bonamino M, Dander E, Marin V, Basso G, Balduzzi A, Biagi E and Biondi A: T-CeIIs stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy. Leukemia 20(11): 2015-2024, 2006.
2. + T-cells efficiently in cancer patients. J Immunother 29(5): 499-511,2006.
3. + memory T-cells migrate in a CD62P-dependent fashion into reactive lymph nodes and license dendritic cells for T-cell priming. J Exp Med 205(11): 2561-2574, 2008.
4. Lehman TL, O'Halloran KP, Fallon SA, Habermann LM, Campbell JA, Nordone S, Dean GA, Hoover EA and Avery PR: Altered bone marrow dendritic cell cytokine production to toll-like receptor and CD40 ligation during chronic feline immunodeficiency virus infection. Immunology 126(3): 405-412,2009.
5. Le Dieu R and Gribben J: CD40 activation: lessons for HIV immunotherapy from malignancies? J HIV Ther 10(3): 51-55, 2005.
6. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, Bajorath J, Grosmaire LS, Stenkamp R and Neubauer M: The CD40 ligand, gp39, is defective in activated T-cells from patients with X-linked hyper-IgM syndrome. Cell 72(2): 291-300, 1993.
7. + T-cells as a marker of disease activity in rheumatoid arthritis. Ann. Rheum Dis 59(3): 190-195, 2000.
8. Lee JK, Seki N, Sayers TJ, Subleski J, Gruys EM, Murphy WJ and Wiltrout RH: Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L. Cell Immunol 135(2): 145-152, 2005.
9. Hollmann CA, Owens T, Nalbantoglu J, Hudson TJ and Sladek R: Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death. Cancer Res 66(7): 3550-3557, 2006.
10. von Euler H, Sadeghi A, Carlsson B, Rivera P, Loskog A, Segall T, Korsgren O and Tötterman TH: Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother 31(4): 377-384,2008.
11. Haenssle H, Buhl T, Knudsen S, Krueger U, Rosenberger A, Reich K and Neumann C: CD40 ligation during dendritic cell maturation reduces cell death and prevents interleukin-10-induced regression to macrophage-like monocytes. Exp Dermatol 17(3): 177-187,2007.
12. Voorzanger-Rousselot N, Alberti L and Blay JY: CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase-independent and -dependent pathways. BMC Cancer 75, 2006.
13. Melichar B, Patenia R, Gallardo S, Melicharovâ K, Hu W and Freedman RS: Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. Gynecol Oncol 104(3): 707-713, 2007.
14. Willimott S, Baou M, Naresh K and Wagner SD: CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br J Haematol 138(6): 721-732, 2007.
15. Liu A, Guardino A, Chinsangaram L, Goldstein MJ, Panicali D and Levy R: Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand. Cancer Res 67(14): 7037-7044, 2007.
16. Murugaiyan G, Martin S and Saha B: CD40-induced counter-current conduits for tumor escape or elimination? Trends Immunol 28(11): 467-473,2007.
17. Masuta Y, Kato K, Tomihara K, Nakamura K, Sasaki K, Takahashi S and Hamada H: Gene transfer of noncleavable cell surface mutants of human CD154 induces the immune response and diminishes systemic inflammatory reactions. J Immunother 30(7): 694-704, 2007.
18. Stewart R, Wei W, Challa A, Armitage RJ, Arrand JR, Rowe M, Young LS, Eliopoulos A and Gordon J: CD154 tone sets the signaling pathways and transcriptome generated in model CD40-pluricompetent L3055 Burkitt's lymphoma cells. J Immunol 179(5): 2705-2712, 2007.
19. Wierda WG and Kipps TJ: Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol 20(3): 557-568, 2007.
20. Hanyu K, Iida T, Shiba H, Ohashi T, Eto Y and Yanaga K. Immunogene therapy by adenovirus vector expressing CD40 ligand for metastatic liver cancer in rats. Anticancer Res 28(5A): 2785-2789,2009.
21. Bensinger WI: Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 23(3): 442-448, 2009.
22. Vesole DH, Zhang L, Flomenberg N, Greipp PR and Lazarus HM: ECOG Myeloma and BMT Committees: A phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. Biol Blood Marrow Transplant 15(1): 83-91, 2009.
23. Fuleihan R, Ramesh N, Horner A, Ahern D, Belshaw PJ, Alberg DG, Stamenkovic I, Harmon W and Geha RS: Cyclosporin A inhibits CD40 ligand expression in T lymphocytes. J Clin Investig 93(3): 1315-1320, 1994.
24. Wu Y, Wang L, He X, Xu H, Zhou L, Zhao F and Zhang Y: Expression of CD40 and growth-inhibitory activity of CD40 ligand in colon cancer ex vivo. Cell Immunol 253(1-2): 102-109, 2008.
25. Buhtoiarov IN, Rakhmilevich AL, Lanier LL, Ranheim EA and Sondel PM: Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules. J Immunol 182(4): 1940-1953,2009.
26. Nau KC and Lewis WD: Multiple myeloma: diagnosis and treatment. Am Fam Physician 78(7): 853-859, 2008.
27. Hirohata S: Human ThI responses driven by IL-12 are associated with enhanced expression of CD40 ligand. Clin. Exp. Immunol 115(1): 78-85, 1999.
28. MacDonald KP, Nishioka Y, Lipsky PE and Thomas R: Functional CD40 ligand is expressed by T-cells in rheumatoid arthritis. J Clin Investig 100(9): 2404-2414, 1979.
29. Sugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, Hara M and Kamatani N: Increased expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40L interaction in IL-6, IL-15, and monocyte chemoattractant protein-1 production. J Immunol 14(8): 6593-6600, 2000.